Two downgrades in as many days have reframed the question hanging over Marvell Technology. The debate is no longer whether the company’s proposed $115 billion acquisition of Lumentum Holdings is bold. It is whether Marvell’s earnings power can carry the dilution that comes with paying for it entirely in stock.
TD Cowen cut the shares from Buy to Hold on the day of the announcement, with analyst Sean O’Loughlin flagging mid-single-digit percentage EPS dilution in calendar 2028. His price target fell from $350 to $175. O’Loughlin also raised concerns about the timing of the transaction — a reminder that when the hit lands matters as much as its size. Bank of America followed with its own downgrade from Buy to Neutral, lowering its target from $400 to $225 and pointing to a potential post-deal share overhang, regulatory delays, and dilution and conflict risks among customers and distribution channels.
Neither move reflects an earnings collapse that has already happened. Both are forward-looking reassessments, and investors would do well to keep that distinction sharp: the projected dilution is a future risk, while Marvell’s latest revenue disclosure concerns the business as it stands today.
A Narrower Range, Not a Higher One
Marvell said yesterday that preliminary revenue for the third quarter of fiscal 2027 is in line with its existing guidance. The midpoint was left untouched. What did change was the width of the forecast, trimmed from plus or minus 5% to plus or minus 2%.
That is a gain in precision, not a lift in the underlying number. No higher revenue level can be inferred from it, and it offers no all-clear on the dilution TD Cowen expects. The two signals point in different directions and cover different horizons. Setting them directly against each other mixes metrics and timeframes; a more defensible case would require operating results that actually absorb the added burden.
Still, a business that meets its expectations is where any bullish scenario has to start. If the tighter range proves durable, investors may find it easier to separate deal risk from operating performance. Confirming a revenue midpoint is not proof that earnings can offset the dilution — but it is a limited, useful anchor.
The Mechanics of the Swap
Under the agreement, Lumentum shareholders would receive 4,500 Marvell shares for each share they hold, with the consideration structured entirely as a stock swap. The implied enterprise value is $115 billion.
That payment form deserves close attention. Paying with one’s own equity is not a free acquisition from the perspective of existing holders, who must weigh the expected benefit against the dilution. The relevant test is not simply what Marvell is buying, but whether the combined company can justify the additional claims on it. Size alone is no argument for value creation — and, by the same token, the share-price reaction does not prove the deal will fail economically.
Should investors sell immediately? Or is it worth buying Marvell Technology?
The merger agreement was signed on Sunday, per Marvell’s mandatory disclosure. Completion is targeted for the first half of calendar 2028 and remains conditional on shareholder and regulatory approvals. Signing and closing are separate events, and for investors that is more than a legal technicality: the announcement sets a framework but supplies neither the required clearances nor later evidence of economic benefit.
Skepticism With a Wider Backdrop
Marvell’s shares fell 13% yesterday as the Lumentum deal was announced, with media reports tying the selloff to worries about the transaction’s scale and the dilution it implies. The market, in other words, is demanding convincing reasons to carry a business of this magnitude rather than rejecting the strategic logic outright.
Part of the nervousness has a broader source. Reuters reported a selloff in chip stocks amid doubts about the sustainability of AI spending, with tighter margins and weakening cash flow also cited as pressures. That environment explains some of the jitters without answering the specific concerns about Marvell’s plan.
The bear case, then, is more than a passing re-rating. It is the prospect of expected dilution colliding with additional business or regulatory strain. The confirmed revenue forecast does not remove those risks, just as the analyst warnings do not confirm that such problems will materialize.
What Would Settle the Argument
As long as Marvell delivers on its operating expectations, the more favorable outcome stays open — provided earnings per share hold up strongly enough. Should EPS come in weaker than anticipated, or should the named transaction risks take concrete form, the cautious stance of the analysts would gain weight.
The expected closing in the first half of 2028 serves as the timeline’s anchor, with shareholder and regulatory sign-offs as the concrete checkpoints ahead. Until then, the sensible split is this: the narrower revenue band supports near-term predictability, while the medium-term valuation rests on how heavily the transaction weighs on earnings per share and whether its conditions for completion are met. Only the interplay of those developments will allow a more grounded reassessment.
Ad
Marvell Technology Stock: Buy or Sell?! New Marvell Technology Analysis from November 3 delivers the answer:
The latest Marvell Technology figures speak for themselves: Urgent action needed for Marvell Technology investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 3.
Marvell Technology: Buy or sell? Read more here...
